Patents by Inventor Yongfei CHEN

Yongfei CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10669238
    Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 2, 2020
    Assignee: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Jing Liu, Qingsong Liu, Qianmao Liang, Yongfei Chen, Cheng Chen, Aoli Wang, Hong Wu, Kailin Yu, Wei Wang, Chen Hu, Wenchao Wang, Shuang Qi, Beilei Wang, Li Wang
  • Patent number: 10670480
    Abstract: An object of the present invention is to provide a thrust testing device for a linear actuator, which can test thrust more accurately and greatly reduce the working intensity of test operators.
    Type: Grant
    Filed: September 30, 2018
    Date of Patent: June 2, 2020
    Assignee: HENGDIAN GROUP INNUOVO ELECTRIC CO., LTD.
    Inventor: Yongfei Chen
  • Patent number: 10350210
    Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 16, 2019
    Assignee: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Jing Liu, Qingsong Liu, Taoshan Jiang, Aoli Wang, Jiaxin Wu, Hong Wu, Ziping Qi, Yongfei Chen, Fengming Zou, Wenchao Wang, Zheng Zhao, Li Wang, Beilei Wang
  • Publication number: 20190195711
    Abstract: An object of the present invention is to provide a thrust testing device for a linear actuator, which can test thrust more accurately and greatly reduce the working intensity of test operators.
    Type: Application
    Filed: September 30, 2018
    Publication date: June 27, 2019
    Inventor: YONGFEI CHEN
  • Publication number: 20190040013
    Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.
    Type: Application
    Filed: December 22, 2016
    Publication date: February 7, 2019
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES
    Inventors: Jing LIU, Qingsong LIU, Qianmao LIANG, Yongfei CHEN, Cheng CHEN, Aoli WANG, Hong WU, Kailin YU, Wei WANG, Chen HU, Wenchao WANG, Shuang QI, Beilei WANG, Li WANG
  • Publication number: 20180369242
    Abstract: The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.
    Type: Application
    Filed: December 15, 2016
    Publication date: December 27, 2018
    Applicant: PRECEDO PHARMACEUTICALS CO., LTD
    Inventors: Jing LIU, Qingsong LIU, Taoshan JIANG, Aoli WANG, Jiaxin WU, Hong WU, Ziping QI, Yongfei CHEN, Fengming ZOU, Wenchao WANG, Zheng ZHAO, Li WANG, Beilei WANG
  • Patent number: 9814709
    Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: November 14, 2017
    Assignees: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD.
    Inventors: Qingsong Liu, Jing Liu, Yongfei Chen, Hong Wu, Aoli Wang, Beilei Wang, Chen Hu, Wenchao Wang, Cheng Chen
  • Publication number: 20170128439
    Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 11, 2017
    Inventors: Qingsong LIU, Jing LIU, Yongfei CHEN, Hong WU, Aoli WANG, Beilei WANG, Chen HU, Wenchao WANG, Cheng CHEN